Werewolf Therapeutics is a highly innovative company that is revolutionizing the field of cancer treatment. They specialize in developing transformative conditionally activated proinflammatory immune modulating medicines, with the aim of unleashing a powerful attack on cancer cells while minimizing off-target effects on non-target tissues. Their technology focuses on creating systemically delivered targeted therapies that address the limitations of immuno-oncology.

Their novel class of cancer biotherapeutics, known as INDUKINE™ molecules, are designed to enhance the body's immune response to cancer. These molecules are delivered in an inactive form and selectively activated upon entering the tumor microenvironment, delivering the full biological potency of cytokines. What sets Werewolf Therapeutics apart is their proprietary PREDATOR™ protein engineering technology.

This cutting-edge approach maximizes therapeutic potential while minimizing unwanted off-target effects, ensuring that patients receive effective and safe cancer immunotherapies. Led by a team of experienced physician-scientists and industry veterans, Werewolf Therapeutics is committed to improving the lives of cancer patients. They bring together expertise in oncology, immunology, and protein engineering to deliver innovative and differentiated cancer therapies.

By redefining the cancer treatment landscape, Werewolf Therapeutics aims to transform the lives of those affected by cancer